Dechra announces partnership with Bioiberica to boost companion animal offering in the United States
Tuesday, January 4, 2022
Dechra is pleased to announce a joint collaboration with Bioiberica, a global Life Science company committed to improving the health and well-being of people, animals and plants, for the license and distribution of its Atopivet® range of dermatology products for cats and dogs in the United States.
The partnership complements Dechra’s existing dermatology range and includes the products Atopivet® Collar, Atopivet® Spot-On, and Atopivet® Mousse. Mike Eldred, President of Dechra North America, states: “The Atopivet® range of dermatology products strengthens Dechra’s popular dermatology product line by offering several unique alternatives to multi-modal dermatology therapy.”
Alfonso Velasco, Companion Animal Director at Bioiberica, adds: “Dermatological problems in canines are one of the most common reasons for veterinary clinic visits. We’re delighted to be partnering with Dechra to bring our Atopivet® range to the United States. We’re already looking ahead to how our collaboration can continue delivering new and innovative approaches to dermatology therapy, supporting the health and quality of life of pets across the region.”
The Atopivet® range will be available in the United States in early 2022. For more information, visit: www.dechra-us.com.
Dechra Veterinary Products’ equine portfolio includes Osphos® (clodronate injection), Orthokine® vet irap 10 and 60, and Osteokine® (PRP). Dechra also offers Equidone® Gel (domperidone), the Vetivex® line of parenteral fluids, Phycox® EQ joint health supplements, and a comprehensive line of topical dermatologic products. The recent additions of ProVet APC™ (Autologous Platelet Concentrate) system and Zimeta® (dipyrone injection) further expand Dechra’s equine offerings.
Bioiberica is a global Life Science company committed to improving the health and well-being of people, animals and plants with more than 45 years of experience. Bioiberica is a leader in the production of the Active Pharmaceutical Ingredient (API) Heparin and an expert in the identification, extraction and development of biologically-derived molecules, which are transformed into high quality products for the pharmaceutical, nutraceutical, veterinary, feed and agricultural sectors.
For questions or further information, please contact Mike Eldred or Doug Hubert:
Mike Eldred, President, North American Operations, Dechra Veterinary Products
Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products